Non-Hodgkin's Lymphoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: B-cell Non Hodgkin Lymphoma Interventions: Drug: DR-0201 Sponsors: Dren Bio; Novotech (Australia) Pty Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
Conditions: NHL; Cutaneous T Cell Lymphoma; Peripheral T-cell Lymphoma Interventions: Biological: BITR2101 Sponsors: Boston Immune Technologies and Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2024 Category: Research Source Type: clinical trials

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
Conditions: Indolent B-Cell Non-Hodgkin Lymphoma; Recurrent Indolent B-Cell Non-Hodgkin Lymphoma; Refractory Indolent B-Cell Non-Hodgkin Lymphoma; Recurrent Indolent Non-Hodgkin Lymphoma; Refractory Indolent Non-Hodgkin Lymphoma Interventions: Procedure: Computed Tomography; Procedure: Endoscopic Procedure; Radiation: Involved-site Radiation Therapy (3 Fractions); Radiation: Involved-site Radiation Therapy (12 Fractions); Procedure: Positron Emission Tomography; Other: Questionnaire Administration Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2024 Category: Research Source Type: clinical trials

A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
Conditions: Hodgkin Lymphoma; Non Hodgkin Lymphoma Interventions: Drug: Omeprazole; Drug: Dextromethorphan Sponsors: Murdoch Childrens Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma, B-Cell; Autologous Stem Cell Transplantation Interventions: Other: Apheresis; Other: Autologous Stem Cell Transplantation; Drug: CAR-T Cell Therapy Sponsors: The First Affiliated Hospital of Soochow University; Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology Hospital, Suzhou, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Conditions: B-NHL, Extranodal, TP53 Alterations, Bulky Mass Interventions: Biological: autologous stem-cell transplantation, Relmacabtagene autoleucel (relma-cel) Sponsors: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy
Conditions: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukaemia; Multiple Myeloma Interventions: Biological: Idecabtagene vicleucel; Biological: Lisocabtagene maraleucel Sponsors: Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Conditions: Acute Lymphoblastic Leukemia,B-Cell; Non-hodgkin Lymphoma,B Cell Interventions: Biological: CD19-BAFF Targeted CAR T-cells Sponsors: Zhejiang University; Shanghai YaKe Biotechnology Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Conditions: B-Cell Non-Hodgkin ' s Lymphoma (NHL); Lymphoma, Non-Hodgkins; Lymphomas Non-Hodgkin ' s B-Cell; Non-Hodgkin Lymphoma; Non-Hodgkin ' s Lymphoma; Large B-Cell Lymphoma; Lymphoma, Non-Hodgkin ' s, Adult; Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; Lymphoma, Non-Hodgkin; HIV Associated Lymphoma; CNS Lymphoma; High-grade B-cell Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma Interventions: Biological: EB103 Sponsors: Estrella Biopharma, Inc.; Eureka Therapeutics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials

Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Conditions: Non-Hodgkin Lymphoma Refractory/ Relapsed Interventions: Biological: CD19 t-haNK Sponsors: ImmunityBio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Conditions: Non-hodgkin Lymphoma Interventions: Biological: TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T); Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
Conditions: Non-hodgkin Lymphoma,B Cell Interventions: Biological: Allogeneic CD19-STAR T cell; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials

A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
Conditions: Non-Hodgkin Lymphoma, B-cell Interventions: Drug: SCTB35 injection Sponsors: Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
Conditions: B-cell Non-Hodgkin ' s Lymphoma Interventions: Biological: RJMty19 (CD19-CAR-DNT cells) Sponsors: Guangdong Ruishun Biotech Co., Ltd; Ruijin Hospital; Southern Medical University, China; Beijing GoBroad Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Interventions: Biological: LUCAR-20SP cells Sponsors: Peking University Cancer Hospital& Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials